☆ 4.7 Article

Molecular rationale for SARS-CoV-2 spike circulating mutations able to escape bamlanivimab and etesevimab monoclonal antibodies

SCIENTIFIC REPORTS (2021)

Related references

Note: Only part of the references are listed.

Review Microbiology

Viral and host heterogeneity and their effects on the viral life cycle

Jennifer E. Jones et al.

Summary: Evidence shows considerable phenotypic and morphological heterogeneity during viral infection, challenging the traditional view of the viral replication cycle. Discussions on the diversity in viral infection include entry receptors, error-prone polymerases, genome packaging, and alternative egress mechanisms such as tunnelling nanotubes and host microvesicles.

NATURE REVIEWS MICROBIOLOGY (2021)

Add to Collection

Review Microbiology

Characteristics of SARS-CoV-2 and COVID-19

Ben Hu et al.

Summary: This review summarizes the research progress on SARS-CoV-2 and COVID-19, including virology characteristics, pathogenesis, and recent advances in treatment methods. Furthermore, it discusses in detail the potential wildlife hosts and zoonotic origin of this emerging virus.

NATURE REVIEWS MICROBIOLOGY (2021)

Add to Collection

Review Biochemistry & Molecular Biology

COVID-19 vaccines: where we stand and challenges ahead

Guido Forni et al.

Summary: The development of vaccines has made significant progress, but still faces various challenges, including different target populations, immunological adaptability of vaccines, and production and distribution issues. To ensure equitable access, protection of diverse subjects, and immunity against viral variants, multiple vaccines may be needed in the long run.

CELL DEATH AND DIFFERENTIATION (2021)

Add to Collection

News Item Multidisciplinary Sciences

ALARMING COVID VARIANTS SHOW KEY ROLE OF GENOMIC SURVEILLANCE

David Cyranoski

NATURE (2021)

Add to Collection

Article Cell & Tissue Engineering

Neutralizing antibodies targeting SARS-CoV-2 spike protein

Shi Xiaojie et al.

Summary: Since it was first identified in Wuhan, China at the end of 2019, SARS-CoV-2 causing the worldwide pandemic has dramatically changed people's lives in multiple aspects. Efforts to curb the progression of the pandemic are urgently ongoing, with promising therapeutic antibodies being developed through various approaches. Studies have shown that neutralizing antibodies against SARS-CoV-2 are mainly targeting the RBD and some non-RBD domains, with convergent germline genes identified for effective antibodies.

STEM CELL RESEARCH (2021)

Add to Collection

Article Biochemistry & Molecular Biology

SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape

Qianqian Li et al.

Summary: The 501Y.V2 variants of SARS-CoV-2 with multiple mutations are rapidly spreading from South Africa to other countries, showing reduced susceptibility to neutralizing antibodies and potential compromise of monoclonal antibodies and vaccines. Enhanced infectivity in murine ACE2-overexpressing cells suggests the possibility of transmission to mice.

CELL (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

Wilfredo F. Garcia-Beltran et al.

Summary: New variants of SARS-CoV-2 show high resistance to vaccine neutralization, with some able to escape vaccine responses with just a few mutations, highlighting the importance of developing broadly protective measures against variants.

CELL (2021)

Add to Collection

Article Microbiology

Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization

Zhuoming Liu et al.

Summary: The study found that antibodies targeting the SARS-CoV-2 spike protein have escape mutations, different monoclonal antibodies have unique resistance profiles, some mutants are resistant to multiple antibodies while some variants can escape neutralization by convalescent sera. Comparing antibody-mediated mutations with circulating SARS-CoV-2 sequences revealed substitutions that may weaken neutralizing immune responses in some individuals, warranting further investigation.

CELL HOST & MICROBE (2021)

Add to Collection

Article Microbiology

Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies

Allison J. Greaney et al.

Summary: The evolution of SARS-CoV-2 may impact the recognition of the virus by human antibody-mediated immunity, with mutations affecting antibody binding varying significantly among individuals and within the same individual over time. Despite this variability, mutations that greatly reduce antibody binding usually occur at specific sites in the RBD, with E484 being the most crucial. These findings can inform surveillance efforts for SARS-CoV-2 evolution in the future.

CELL HOST & MICROBE (2021)

Add to Collection

Article Multidisciplinary Sciences

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

Dami A. Collier et al.

Summary: The B.1.1.7 variant of SARS-CoV-2 exhibited reduced neutralization by vaccines and antibodies from recovered COVID-19 patients, with a more substantial loss seen when introducing the E484K mutation. This mutation poses a threat to the efficacy of the BNT162b2 vaccine.

NATURE (2021)

Add to Collection

News Item Multidisciplinary Sciences

HOW TO REDESIGN COVID VACCINES SO THEY PROTECT AGAINST VARIANTS

Ewen Callaway et al.

NATURE (2021)

Add to Collection

Article Multidisciplinary Sciences

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Pengfei Wang et al.

Summary: The COVID-19 pandemic has had global repercussions, with promising vaccines and monoclonal antibody therapies. However, newly detected variants of SARS-CoV-2 present challenges to these treatment options.

NATURE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies

Rita E. Chen et al.

Summary: The study analyzed antibody neutralization activity against a panel of authentic isolates and chimeric SARS-CoV-2 variants, showing significantly reduced neutralizing activity against the B.1.351 variant first identified in South Africa. Antibodies targeting the receptor-binding domain and N-terminal domain, monoclonal antibodies, convalescent sera, and mRNA vaccine-induced immune sera exhibited decreased inhibitory activity against viruses with an E484K spike mutation, suggesting a need for updated monoclonal antibodies or vaccine adjustments to prevent loss of protection against emerging variants.

NATURE MEDICINE (2021)

Add to Collection

Article Virology

SARS-CoV-2 Variant of Concern 202012/01 Has about Twofold Replicative Advantage and Acquires Concerning Mutations

Frederic Grabowski et al.

Summary: The novel SARS-CoV-2 Variant of Concern (VOC)-202012/01, known as B.1.1.7, first identified in the UK in September 2020, has rapidly spread globally and is of concern due to its potential impact on vaccine effectiveness. The VOC has acquired significant mutations, including some that may compromise the binding of neutralizing antibodies, and it is essential to monitor its molecular evolution to understand its impact on the ongoing pandemic.

VIRUSES-BASEL (2021)

Add to Collection

Article Multidisciplinary Sciences

SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface

Federico Bertoglio et al.

Summary: COVID-19 is a severe acute respiratory disease caused by SARS-CoV-2, which utilizes human ACE2 enzyme as receptor for cell entry. Researchers have used phage display to select anti-SARS-CoV-2 spike antibodies from universal antibody gene libraries, showing potential inhibition of infection.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Chemistry, Multidisciplinary

Computational Mutagenesis at the SARS-CoV-2 Spike Protein/Angiotensin-Converting Enzyme 2 Binding Interface: Comparison with Experimental Evidence

Erik Laurini et al.

Summary: This study focused on in silico mutating ACE2 and S-protein residues to study the effects of different amino acids on the structure and strength of the binding interface, with a subsequent validation against experimental data yielding an overall agreement of 92%. Predictions were made that certain missense variations could enhance ACE2/S-RBDCoV-2 binding.

ACS NANO (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant

Xianding Deng et al.

Summary: A new SARS-CoV-2 variant named B.1.427/B.1.429 was identified in California, with increased transmissibility and carrying three mutations in spike protein, including L452R substitution. The variant emerged in May 2020 and became predominant in sequenced cases from September 2020 to January 2021. In vivo viral shedding was increased and antibody neutralization decreased, calling for further investigation.

CELL (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Antibody evasion by the P.1 strain of SARS-CoV-2

Wanwisa Dejnirattisai et al.

Summary: Ending the SARS-CoV-2 pandemic requires global vaccination. New virus strains with mutations impact antibody responses, but some variants are less resistant than others. A monoclonal antibody can neutralize different variants and partially restore neutralization potency for other public antibodies.

CELL (2021)

Add to Collection

Article Multidisciplinary Sciences

Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma

Sandile Cele et al.

Summary: The study compared the neutralization of non-VOC and 501Y.V2 VOC variants using plasma from COVID-19 patients in South Africa. It found that plasma from individuals infected during the first wave effectively neutralized the first-wave virus variant, while plasma from those infected in the second wave effectively neutralized the 501Y.V2 variant.

NATURE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

Delphine Planas et al.

Summary: The ability of convalescent sera from individuals with coronavirus disease 2019 and those vaccinated with BNT162b2 to neutralize SARS-CoV-2 variants B1.1.7 and B.1.351 decreases, but increases after two vaccine doses. The study found that the B.1.1.7 and B.1.351 variants may have acquired partial resistance to neutralizing antibodies generated by natural infection or vaccination, particularly in individuals with low antibody levels. This suggests that the B.1.351 variant may pose a greater risk of infection in immunized individuals.

NATURE MEDICINE (2021)

Add to Collection

Editorial Material Biochemistry & Molecular Biology

SARS-CoV-2 escaped natural immunity, raising questions about vaccines and therapies

Emanuele Andreano et al.

Summary: While SARS-CoV-2 is capable of evading natural immune responses, the question remains whether the virus can escape monoclonal antibodies and vaccine-induced immunity.

NATURE MEDICINE (2021)

Add to Collection

Review Virology

Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines

Daniele Focosi et al.

Summary: The Spike protein serves as the target for antibody-based therapeutics and vaccines, but mutations in Spike could impact their efficacy. Monitoring mutations is crucial for adjusting the therapeutics inventory. Different clades exhibit varying mutation combinations, with a focus on the UK, South African, and Brazilian variants.

REVIEWS IN MEDICAL VIROLOGY (2021)

Add to Collection

Article Cell Biology

The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates

Bryan E. Jones et al.

Summary: LY-CoV555 is a novel neutralizing antibody derived from a convalescent patient with COVID-19, showing high affinity binding, potent inhibition of ACE2 binding, and strong neutralizing activity. This antibody has entered clinical trials and is being evaluated for various COVID-19 prevention and treatment indications.

SCIENCE TRANSLATIONAL MEDICINE (2021)

Add to Collection

Review Chemistry, Multidisciplinary

A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development

Yingzhu Li et al.

Summary: The report examines a significant number of vaccine candidates for the COVID-19 pandemic that emerged last year, discussing their technological advantages and disadvantages, the use of adjuvants and delivery systems, and providing insights into their future direction.

ACS CENTRAL SCIENCE (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Antibodies and Vaccines Target RBD of SARS-CoV-2

Long Min et al.

Summary: Following the outbreak of the pandemic, the development of neutralizing antibodies and vaccines targeting the coronavirus has become crucial, with RBD being identified as the key research target.

FRONTIERS IN MOLECULAR BIOSCIENCES (2021)

Add to Collection

Article Microbiology

SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity

Chihiro Motozono et al.

Summary: Research has shown that certain mutations in SARS-CoV-2 variants can escape HLA-restricted cellular immunity, increase affinity for host cells, promote viral replication, and potentially affect the evolution of viral phenotypes.

CELL HOST & MICROBE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Revealing the Threat of Emerging SARS-CoV-2 Mutations to Antibody Therapies

Jiahui Chen et al.

Summary: The ongoing vaccination and development of intervention offer hope to end the global COVID-19 pandemic, but emerging SARS-CoV-2 variants could compromise existing vaccines and antibody therapies. Studies on potential threats from mutations are limited, and the impact on clinical trial antibodies is largely unknown.

JOURNAL OF MOLECULAR BIOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

Emergence and expansion ofSARS-CoV-2 B.1.526 after identification in New York

Medini K. Annavajhala et al.

Summary: The emergence of the B.1.526 lineage of SARS-CoV-2, with mutations such as E484K, has led to its rapid dominance in New York City. This variant is resistant to therapeutic monoclonal antibodies and less susceptible to neutralization by antibodies from recovered or vaccinated individuals, contributing to its fast spread.

NATURE (2021)

Add to Collection

Article Multidisciplinary Sciences

SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern

Matthew McCallum et al.

Summary: The novel CAL.20C (B.1.427/B.1.429) variant carries spike protein mutations, resulting in reduced neutralizing titers in vaccinated individuals and convalescent individuals. The L452R mutation reduces neutralizing activity in RBD-specific monoclonal antibodies, while the S13I and W152C mutations lead to the total loss of neutralization in NTD-specific antibodies due to antigenic supersite remodeling.

SCIENCE (2021)

Add to Collection

Article Multidisciplinary Sciences

Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies

Allison J. Greaney et al.

Summary: The study found that although the human immune system can produce antibodies that target diverse RBD epitopes, in practice, the polyclonal response to infection tends to be skewed towards a single class of antibodies targeting an epitope that is already undergoing rapid evolution.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Cell Biology

One-shot identification of SARS-CoV-2 S RBD escape mutants using yeast screening

Irene M. Francino-Urdaniz et al.

Summary: This study reveals the presence of escape mutants for five nAbs targeting the S receptor binding site, predominantly located on the periphery of the ACE2 recognition site. The research team provides libraries, methods, and software as an openly available community resource to expedite the development of new therapeutic strategies against SARS-CoV-2.

CELL REPORTS (2021)

Add to Collection

Article Cell Biology

SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination

Markus Hoffmann et al.

Summary: The emergence of the B.1.617 variant in India may be responsible for the sharp increase in COVID-19 cases and deaths. B.1.617 shows increased efficiency in entering cells and evades antibody responses, contributing to its rapid spread.

CELL REPORTS (2021)

Add to Collection

Article Immunology

Comparative Analysis of Emerging B.1.1.7+E484K SARS-CoV-2 Isolates

Ahmed M Moustafa et al.

Open Forum Infectious Diseases (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Development and application of therapeutic antibodies against COVID-19

Lin Ning et al.

Summary: The global health crisis caused by the COVID-19 pandemic continues, with many therapeutic antibody treatments in development and authorized for emergency use by the FDA. Ongoing clinical trials worldwide have shown therapeutic antibody therapies to be a crucial part of COVID-19 treatment.

INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Priming of SARS-CoV-2 S protein by several membrane-bound serine proteinases could explain enhanced viral infectivity and systemic COVID-19 infection

Pablo Fuentes-Prior

Summary: The COVID-19 pandemic has caused over a million deaths worldwide, and the death toll is expected to rise further before effective treatments and vaccines are available. The causative agent, SARS-CoV2, has significant differences from the previous SARS-CoV-1 and has a higher transmission rate, affecting multiple organs in addition to the lungs. Understanding the role of membrane-associated serine proteinases (MASPs) in the activation of the virus spike protein could potentially help in controlling the pandemic.

JOURNAL OF BIOLOGICAL CHEMISTRY (2021)

Add to Collection

Letter Infectious Diseases

SARS-CoV-2 spike E484K mutation reduces antibody neutralisation

Sonia Jangra et al.

LANCET MICROBE (2021)

Add to Collection

Article Medicine, Research & Experimental

501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro

Haolin Liu et al.

Summary: The newly emerging variants of SARS-CoV-2 from South Africa and Brazil have led to a higher infection rate and reinfection of COVID-19 patients. Mutations within the receptor-binding domains of the virus increase binding affinity to the human receptor ACE2 and affect the binding of therapeutic antibodies.

MABS (2021)

Add to Collection

Review Immunology

Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection

Deborah Cromer et al.

Summary: The duration of immunity to COVID-19 and the risk of reinfection remain unclear. Immunity is crucial for long-term control of the pandemic, but studies suggest a decline in antibody responses and an increase in documented cases of reinfection with SARS-CoV-2. Understanding memory responses and immune control dynamics is essential for designing vaccines and predicting the future trajectory of the pandemic.

NATURE REVIEWS IMMUNOLOGY (2021)

Add to Collection

Article Cell Biology

Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016

Tyler N. Starr et al.

Summary: The study mapped mutations to the SARS-CoV-2 spike receptor-binding domain that escape binding by certain monoclonal antibodies. These mutations are concentrated in specific lineages of SARS-CoV-2. The authors suggest diversifying the epitopes targeted by antibodies and antibody cocktails to make them more resilient to SARS-CoV-2 antigenic evolution.

CELL REPORTS MEDICINE (2021)

Add to Collection

Review Immunology

Neutralizing monoclonal antibodies for treatment of COVID-19

Peter C. Taylor et al.

Summary: The study discusses the clinical utility of neutralizing monoclonal antibody therapies targeting SARS-CoV-2, emphasizing the importance of patient stratification, biomarkers, risk factors, and other clinical considerations.

NATURE REVIEWS IMMUNOLOGY (2021)

Add to Collection

Review Microbiology

Coronavirus biology and replication: implications for SARS-CoV-2

Philip V'kovski et al.

Summary: This review discusses key aspects of coronavirus biology and their implications for SARS-CoV-2 infections, treatment, and prevention strategies. Understanding virus-host interactions at the molecular level is crucial for developing effective intervention strategies. Summarizing the discoveries of SARS-CoV-2 infection and comparing it with other coronaviruses will support future preparedness and combat strategies.

NATURE REVIEWS MICROBIOLOGY (2021)

Add to Collection

Editorial Material Medicine, General & Internal

Connecting With Patients-The Missing Links

Lisa Sanders et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Medicine, General & Internal

A Novel Coronavirus from Patients with Pneumonia in China, 2019

Na Zhu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Multidisciplinary Sciences

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

Renhong Yan et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Daniel Wrapp et al.

SCIENCE (2020)

Add to Collection

Article Microbiology

We shouldn't worry when a virus mutates during disease outbreaks

Nathan D. Grubaugh et al.

NATURE MICROBIOLOGY (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2

Qihui Wang et al.

CELL (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Alexandra C. Walls et al.

CELL (2020)

Add to Collection

Article Biochemistry & Molecular Biology

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Markus Hoffmann et al.

CELL (2020)

Add to Collection

Article Immunology

Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies

Chunyan Yi et al.

CELLULAR & MOLECULAR IMMUNOLOGY (2020)

Add to Collection

Editorial Material Immunology

Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses

Shibo Jiang et al.

TRENDS IN IMMUNOLOGY (2020)

Add to Collection

Article Multidisciplinary Sciences

Evidence for host-dependent RNA editing in the transcriptome of SARS-CoV-2

Salvatore Di Giorgio et al.

SCIENCE ADVANCES (2020)

Add to Collection

Article Multidisciplinary Sciences

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

Rui Shi et al.

NATURE (2020)

Add to Collection

Article Multidisciplinary Sciences

Cross-neutralization ofSARS-CoV-2 by a human monoclonal SARS-CoV antibody

Dora Pinto et al.

NATURE (2020)

Add to Collection

Article Multidisciplinary Sciences

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Jun Lan et al.

NATURE (2020)

Add to Collection

Article Biochemistry & Molecular Biology

The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity

Qianqian Li et al.

CELL (2020)

Add to Collection

Editorial Material Medicine, General & Internal

Is a Cytokine Storm Relevant to COVID-19?

Pratik Sinha et al.

JAMA INTERNAL MEDICINE (2020)

Add to Collection

Review Immunology

Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies

Yujun Tang et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Review Medicine, General & Internal

Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19) A Review

W. Joost Wiersinga et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Chemistry, Multidisciplinary

Computational Alanine Scanning and Structural Analysis of the SARS-CoV-2 Spike Protein/Angiotensin-Converting Enzyme 2 Complex

Erik Laurini et al.

ACS NANO (2020)

Add to Collection

Article Biophysics

Review of COVID-19 Antibody Therapies

Jiahui Chen et al.

Annual Review of Biophysics (2020)

Add to Collection

Review Biochemistry & Molecular Biology

Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting

Fran Robson et al.

MOLECULAR CELL (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology

Luca Piccoli et al.

CELL (2020)

Add to Collection

Article Multidisciplinary Sciences

Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion

Donald J. Benton et al.

NATURE (2020)

Add to Collection

Editorial Material Biotechnology & Applied Microbiology

COVID-19 antibodies on trial

Linda J. Saif et al.

NATURE BIOTECHNOLOGY (2020)

Add to Collection

Article Multidisciplinary Sciences

Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate

Sandhya Bangaru et al.

SCIENCE (2020)

Add to Collection

Review Multidisciplinary Sciences

A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity

Angkana T. Huang et al.

NATURE COMMUNICATIONS (2020)

Add to Collection

News Item Medicine, General & Internal

Covid-19: RECOVERY trial will evaluate antiviral antibody cocktail

Elisabeth Mahase

BMJ-BRITISH MEDICAL JOURNAL (2020)

Add to Collection

Editorial Material Medicine, General & Internal

Neutralizing Antibodies Against SARS-CoV-2-Important Questions, Unclear Answers

Mitchell H. Katz

JAMA INTERNAL MEDICINE (2020)

Add to Collection

Article Immunology

Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients

Anita S. Iyer et al.

SCIENCE IMMUNOLOGY (2020)

Add to Collection

Article Biology

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

Yiska Weisblum et al.

ELIFE (2020)

Add to Collection

Review Biochemistry & Molecular Biology

Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2

Fei Yu et al.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)

Add to Collection

Review Cell Biology

Development of therapeutic antibodies for the treatment of diseases

Ruei-Min Lu et al.

JOURNAL OF BIOMEDICAL SCIENCE (2020)

Add to Collection

Review Chemistry, Multidisciplinary

End-Point Binding Free Energy Calculation with MM/PBSA and MM/GBSA: Strategies and Applications in Drug Design

Ercheng Wang et al.

CHEMICAL REVIEWS (2019)

Add to Collection

Article Cardiac & Cardiovascular Systems

Biomechanical defects and rescue of cardiomyocytes expressing pathologic nuclear lamins

Erik Laurini et al.

CARDIOVASCULAR RESEARCH (2018)

Add to Collection

Article Chemistry, Medicinal

Interaction Entropy for Computational Alanine Scanning

Yuna Yan et al.

JOURNAL OF CHEMICAL INFORMATION AND MODELING (2017)

Add to Collection

Article Chemistry, Physical

Interaction entropy for protein-protein binding

Zhaoxi Sun et al.

JOURNAL OF CHEMICAL PHYSICS (2017)

Add to Collection

Article Oncology

β-Catenin in desmoid-type fibromatosis: deep insights into the role of T41A and S45F mutations on protein structure and gene expression

Chiara Colombo et al.

MOLECULAR ONCOLOGY (2017)

Add to Collection

Article Multidisciplinary Sciences

Mitochondrial dysfunction induced by a SH2 domain-targeting STAT3 inhibitor leads to metabolic synthetic lethality in cancer cells

Davide Genini et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)

Add to Collection

Article Chemistry, Multidisciplinary

Interaction Entropy: A New Paradigm for Highly Efficient and Reliable Computation of Protein-Ligand Binding Free Energy

Lili Duan et al.

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2016)

Add to Collection

Article Multidisciplinary Sciences

Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody

Davide Corti et al.

SCIENCE (2016)

Add to Collection

Article Chemistry, Physical

ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB

James A. Maier et al.

JOURNAL OF CHEMICAL THEORY AND COMPUTATION (2015)

Add to Collection

Article Biotechnology & Applied Microbiology

Target sequencing approach intended to discover new mutations in non-syndromic intellectual disability

Anna Morgan et al.

MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2015)

Add to Collection

Article Biochemistry & Molecular Biology

The Sigma Enigma: In Vitro/in Silico Site-Directed Mutagenesis Studies Unveil σ1 Receptor Ligand Binding

S. Brune et al.

BIOCHEMISTRY (2014)

Add to Collection

Article Multidisciplinary Sciences

Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy

Don L. Gibbons et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)

Add to Collection

Article Medicine, Research & Experimental

In vitro and in silico studies of MDM2/MDMX isoforms predict Nutlin-3A sensitivity in well/de-differentiated liposarcomas

Fabio Bozzi et al.

LABORATORY INVESTIGATION (2013)

Add to Collection

Review Immunology

Developments and Challenges for mAb-Based Therapeutics

Sumit Goswami et al.

ANTIBODIES (2013)

Add to Collection

Article Biochemistry & Molecular Biology

H++3.0: automating pK prediction and the preparation of biomolecular structures for atomistic molecular modeling and simulations

Ramu Anandakrishnan et al.

NUCLEIC ACIDS RESEARCH (2012)

Add to Collection

Review Oncology

Targeted therapy in GIST: in silico modeling for prediction of resistance

Marco A. Pierotti et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2011)

Add to Collection

Review Chemistry, Multidisciplinary

GLYCAM06: A generalizable Biomolecular force field. Carbohydrates

Karl N. Kirschner et al.

JOURNAL OF COMPUTATIONAL CHEMISTRY (2008)

Add to Collection

Article Chemistry, Multidisciplinary

UCSF chimera - A visualization system for exploratory research and analysis

EF Pettersen et al.

JOURNAL OF COMPUTATIONAL CHEMISTRY (2004)

Add to Collection

Article Chemistry, Physical

Efficient particle-mesh Ewald based approach to fixed and induced dipolar interactions

A Toukmaji et al.

JOURNAL OF CHEMICAL PHYSICS (2000)

Add to Collection

Article Biochemistry & Molecular Biology

The Protein Data Bank

HM Berman et al.

NUCLEIC ACIDS RESEARCH (2000)

Add to Collection

© Peeref 2019-2024. All rights reserved.